Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Read quietly unpicks Pfizer’s Indian generics legacy

This article was originally published in Scrip

Executive Summary

Pfizer isn’t saying much, and neither is Aurobindo. But it looks as if the two companies are at least scaling down their 2009 alliance for off-patent medicines, and that they are downgrading the expectations that accompanied the deal. A key factor in the transition is believed to be Pfizer CEO Ian Read, and to his intention to reel back some of the bolder steps towards generic that occurred under his predecessor, Jeff Kindler.



Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts